Current pharmaceutical design最新文献

{"title":"CRISPR-Edited Cell Lines: A New Era in Functional Oncology Research.","authors":"Amita Joshi Rana, Md Sadique Hussain, Ali Hanbashi, Faroq Kamli, Gyas Khan, Marwa Qadri, Saeed A Al-Qahtani, Mohammad Gayoor Khan, Sushil S Burle, Vikas Jakhmola, Gaurav Gupta","doi":"10.2174/0113816128413220250728182852","DOIUrl":"https://doi.org/10.2174/0113816128413220250728182852","url":null,"abstract":"<p><p>The use of CRISPR-Cas9 to engineer cancer cell lines has made it possible to precisely examine how cancer cells react to different drugs and therapies. Some of the key improvements are in the use of Mediator Complex Subunit 12 (MED12)-knockout cells to study cell resistance to BRAF inhibitors, CRISPR models of Epithelial-Mesenchymal Transition for breast cancer, and pharmacogenomic analysis in various cancer cell lines. CRISPR is used in immunotherapy to help Chimeric Antigen Receptor T (CAR-T) cells function better by disrupting the immune checkpoints like Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-lymphocyte- associated protein 4 (CTLA-4) and to adapt T cells to react with various antigens. As a result of these innovations, it is now possible to track how cancers like non-small cell lung cancer (NSCLC) and ovarian cancer evolve, change their epigenetic features, and find strategies to reverse their resistance. Moving forward, mixing AI analytics, single-cell multi-omics, patient-derived organoids, and CRISPR mechanisms will help improve precision oncology and speed up effective treatment planning.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-Endogenous Nanoformulation for Endocannabinoid and Hormonal Modulation of Key Signaling Pathways in Resistant Hypertension.","authors":"Virna Margarita Martín Giménez, Sebastián García Menéndez, Walter Manucha","doi":"10.2174/0113816128396666250728074858","DOIUrl":"https://doi.org/10.2174/0113816128396666250728074858","url":null,"abstract":"<p><p>Despite notable advances in the development of synthetic antihypertensive therapies, resistant hypertension remains a complex and challenging condition. Its persistence is attributed to multifactorial resistance mechanisms involving several key signaling pathways, including Hsp70, WT1, AT1, and iNOS. A promising therapeutic strategy involves the simultaneous modulation of these pathways using endogenous bioactive compounds delivered via controlled and sustained-release nanosystems. Such nanoformulations enable the co-delivery of multiple agents, enhancing their bioavailability, stability, and therapeutic precision. This multifaceted approach allows for more effective modulation of the underlying pathophysiological processes of hypertension, including inflammation, oxidative stress, and vascular dysfunction. By integrating these compounds into a single delivery platform, nanoformulations may offer a significant advancement in the treatment of resistant hypertension and related cardiovascular disorders. Future research should prioritize the optimization of these delivery systems and the assessment of their efficacy in clinically relevant models.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Formulation and in vitro Evaluation of Targeted Chemotherapy of Crizotinib-loaded polymeric Nanoparticles on Cancer Cell Lines.","authors":"Faiza Naureen, Yasar Shah, Maqsood Ur Rehman, Reem M Alnemari","doi":"10.2174/0113816128412622250730015435","DOIUrl":"https://doi.org/10.2174/0113816128412622250730015435","url":null,"abstract":"<p><strong>Introduction: </strong>Crizotinib, an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, holds significant potential for the treatment of lung cancer. However, its toxicities present a major challenge to its clinical use. To enhance the targeted delivery of Crizotinib to lung tumors, polymeric-based nanoparticles were developed.</p><p><strong>Methods: </strong>Crizotinib-loaded polymeric nanoparticles were prepared using a nano-precipitation method, incorporating stearic acid as the lipid, polyethylene glycol as the polymer, and Tween 80 as the surfactant. Key formulation parameters were optimized to achieve high-quality nanoparticles.</p><p><strong>Results: </strong>The optimized formulation exhibited a mean particle size of 142 nm, a zeta potential of -31.9 mV, an entrapment efficiency of 82.35%, and an in vitro drug release of 60.69%. These nanoparticles were then tested on lung cancer cell lines to assess their cytotoxicity, apoptosis induction, and anti-proliferative effects on the cell cycle. In vitro studies confirmed that the Crizotinib-loaded nanoparticles exerted targeted effects on nonsmall cell lung carcinoma (NSCLC) cell lines, showing maximum inhibitory effects. One year of storage at 4°C, stability testing demonstrated that the lyophilized nanoparticles maintained their effectiveness.</p><p><strong>Discussion: </strong>crizotinib nano-formulations were assessed for a variety of physicochemical and in vitro characterization . Five different formulations were designed and optimized on the basis of Particle size, Zeta potential, %EE, and in vitro drug release. Optimum formulation also showed maximum inhibitory effect on the cancer cell line.</p><p><strong>Conclusion: </strong>This nanotechnology approach offers a promising targeted drug delivery system for Crizotinib, characterized by small particle size, high encapsulation efficiency (EE), and optimal in vitro drug release.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Insight into Pharmaceutical Design and Pharmacokinetic Characteristics of GLP-1 RAs.","authors":"Mohamed F Zayed, Nada O Khyat, Rawan W Alsibyani, Rahaf Z Alshami, Ramzyah A Alsubahi, Mariam K Alamoudi","doi":"10.2174/0113816128375766250720234005","DOIUrl":"https://doi.org/10.2174/0113816128375766250720234005","url":null,"abstract":"<p><strong>Introdcution: </strong>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are among the most effective treatments for type 2 diabetes mellitus (T2DM). GLP-1 RAs stimulate pancreatic receptors, improving glycemia by boosting insulin secretion while decreasing glucagon secretion. GLP-1 receptors are present in pancreatic tissue. They are also found in extra-pancreatic tissue and have been shown to reduce body weight while also protecting the heart and endothelial cells. The most prevalent types of GLP-1 RAs can be injected twice daily (exenatide), once daily (lixisenatide and liraglutide), or once weekly (albiglutide, dulaglutide, exenatide once, semaglutide, tirzepatide). GLP-1 receptor agonists also reduce gastric emptying, preventing substantial post-meal glycaemic increases. Many publications have been written regarding GLP-1 RAs, covering various features of this family. However, the purpose of this study is to investigate the pharmacological design models and pharmacokinetic characteristics of the most regularly used members of this class, as well as to highlight contemporary developments in GLP-1 RAs. It also describes the physicochemical features, techniques of manufacture, the effects of molecular structure, and structural modifications on pharmacological activity.</p><p><strong>Methods: </strong>The literature review was completed using a structured approach to identify and integrate relevant literature. It involved a broad search of reputable medical databases using inclusion and exclusion criteria.</p><p><strong>Result: </strong>They are classified as short-acting or long-acting based on the length of their action. Short-acting GLP-1 RAs and long-acting GLP-1 RAs have differing efficacy profiles. Furthermore, the methods of administration, mode of action, and side effects of these medications are relevant to their pharmacological design and pharmacokinetic properties.</p><p><strong>Discussion: </strong>The treatment of type 2 diabetes and obesity has evolved with the advent of GLP-1 RAs. These drugs have a multifaceted approach, emphasizing glycemic regulation, weight loss, and reduction of cardiovascular risk. Their unique mode of action, strong safety profile, and ability to be individualized according to each patient's needs make them a valuable therapeutic option in the management of metabolic disorders. Their pharmacological activities are also influenced by their different structural and pharmacokinetic properties.</p><p><strong>Conclusion: </strong>GLP-1 RAs have a complex strategy due to their pharmacological nature. The variations in their design have led to various members with varying pharmacodynamic and pharmacokinetic features.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144834444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microemulsion Loaded Hydrogel as an Advanced Approach for Topical Delivery of Drug: A Brief Review.","authors":"Nitin Singh, Charanjeet Singh, Satyam Khare, Preeti Patel, Wasim Akram, Ramakant Joshi, Balak Das Kurmi","doi":"10.2174/0113816128379742250720131311","DOIUrl":"https://doi.org/10.2174/0113816128379742250720131311","url":null,"abstract":"<p><p>Topical drug delivery has emerged as a promising alternative to conventional oral and parenteral routes, particularly for localized treatment and enhanced patient compliance. However, challenges such as poor drug solubility, low skin permeability, and instability of conventional formulations limit their effectiveness. To address these limitations, microemulsion-loaded hydrogels have gained significant attention as an advanced and efficient drug delivery system for topical applications. Microemulsions are thermodynamically stable, clear, isotropic mixtures of oil, water, surfactant, and co-surfactant that offer improved drug solubilization and skin penetration. When incorporated into hydrogels, they combine the penetration-enhancing properties of microemulsions with the viscosity and spreadability of hydrogels, resulting in a stable, non-greasy, and easily applicable formulation. This review highlights the fundamental characteristics of microemulsion-based hydrogels, including their composition and advantages over conventional topical systems. The synergistic effect of microemulsions and hydrogels enhances the drug loading capacity, prolongs drug release, and improves bioavailability, especially for hydrophobic and poorly permeable drugs. Furthermore, these systems minimize systemic side effects and improve patient adherence due to their non-invasive nature and ease of application. The review also discusses various examples of drugs successfully delivered through this platform, including antifungals, anti-inflammatories, and analgesics. Overall, microemulsion-loaded hydrogels represent a promising and innovative approach for effective topical drug delivery. With ongoing research and formulation advancements, they hold great potential for future clinical applications in dermatology and transdermal therapy.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144834446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Potential Mechanism of Smilax Glabra Roxb in Periodontitis Through Network Pharmacology and Molecular Docking.","authors":"Jinjia Hong, Peilun Ma, Yuan Zhang, Na Li, Pengfei Zhang, Chunrui Tian, Yukang Cao, Xing Wang","doi":"10.2174/0113816128391490250729102829","DOIUrl":"https://doi.org/10.2174/0113816128391490250729102829","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to explore the potential mechanisms of Smilax Glabra Roxb (SGR) in the treatment of periodontitis using network pharmacology and molecular docking.</p><p><strong>Methods: </strong>The active components and targets of SGR were identified using the TCMSP, STITCH, and SwissTargetPrediction databases, while periodontitis-related targets were retrieved from GeneCards, TTD, and OMIM. Overlapping targets were subjected to Protein-Protein Interaction (PPI) analysis via the STRING platform, followed by network analysis using Cytoscape software and the MCODE plugin to identify key protein targets. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were conducted through the DAVID database to determine relevant biological processes and pathways. Finally, molecular docking was performed to assess the binding affinity between the key active components of SGR and critical target and pathway proteins.</p><p><strong>Results: </strong>A total of 15 active components and 527 potential targets of SGR were identified, along with 367 targets related to periodontitis. The 75 overlapping targets were considered potential therapeutic targets. Key genes, such as IL-6, IL-1β, and TNF, were identified through Cytoscape analysis. KEGG enrichment analysis indicated that the overlapping targets are primarily involved in inflammatory and metabolic pathways, including the AGE-RAGE signaling pathway, the lipid and atherosclerosis pathway, and the TNF signaling pathway. Molecular docking results showed that the key active components can stably bind to the critical targets and pathway proteins.</p><p><strong>Discussion: </strong>SGR may have particular advantages in treating periodontitis in patients with systemic diseases, such as diabetes and cardiovascular conditions, but further research is needed to validate its clinical efficacy and safety.</p><p><strong>Conclusion: </strong>This study highlights the therapeutic potential of SGR in the treatment of periodontitis and elucidates its possible molecular mechanisms, offering new insights and targets for periodontitis therapy.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144834445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Artificial Intelligence in Modern Medicine: Clinical Applications, Economic Implications, and Ethical Considerations.","authors":"R Kamalesh, P Thamarai, Alan Shaji, V C Deivayanai, A Saravanan, A S Vickram, Thanigaivel Sundaram, Hitesh Chopra","doi":"10.2174/0113816128388946250717182703","DOIUrl":"https://doi.org/10.2174/0113816128388946250717182703","url":null,"abstract":"<p><p>Artificial Intelligence (AI) in the medical field has been receiving attention from health professionals and researchers worldwide. The complexity and challenging aspects of healthcare are transformed by AI, with the potential for improvement in patient care and quality of life. The advancements in AI can revolutionize healthcare through integration into clinical practice. These tools can analyse vast datasets and detect patterns, enabling them to exceed human performance in various aspects of healthcare. Implementing augmented medicines allows for superior autonomy and personalised treatment among patients. The increase in the inclusion of AI in medical frontiers has created the need to validate these tools with clinical trials towards the upgrade of medical curriculum with digital medicine and ethical considerations on current monitoring. The current review aimed to discuss the evolution of AI in promising avenues of healthcare such as diagnostics, medical imaging, drug development, clinical trials, surgery, and patient monitoring. The review also addresses the economic impact of AI in healthcare, followed by the efficiency and financial impact on patients and hospitals. Despite the beneficial impact, several challenges, such as ethical and regulatory concerns, also influence the integration of AI. By tackling these challenges, AI's potential can be fully realized, making healthcare more accessible to patients worldwide.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144815958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-cancer Drugs in Endometriosis Management: Mechanisms and Therapeutic Potential.","authors":"Marzieh Neykhonji, Abdulridha Mohammed Al-Asady, Hanieh Akbarzadeh, Amir Avan, Majid Khazaei, Seyed Mahdi Hassanian","doi":"10.2174/0113816128387356250720042300","DOIUrl":"https://doi.org/10.2174/0113816128387356250720042300","url":null,"abstract":"<p><strong>Introduction: </strong>Endometriosis is a widespread estrogen-driven condition causing pelvic pain and infertility in women. This disease shares five features with cancer: Intrinsic growth signals, insensitivity to antiproliferative signals, impaired apoptosis, induction of angiogenesis, and heightened tissue invasion, suggesting common therapeutic targets for both conditions. This article reviews studies investigating the anti-cancer drugs' protective effects and mechanisms in endometriosis treatment, providing essential insights into their efficacy and the relevant pathways in managing the disease.</p><p><strong>Methods: </strong>A comprehensive review was conducted to assess the potential therapeutic benefits of anti-cancer drugs in endometriosis treatment. This included an extensive search of Google Scholar and PubMed, using relevant keywords without any limitations untilthe end of 2024, to ensure a thorough analysis of existing research in this field.</p><p><strong>Results: </strong>Many drugs used in treating estrogen-dependent and other cancers have demonstrated significant therapeutic potential for endometriosis, as supported by cellular, animal, and clinical studies.</p><p><strong>Discussion: </strong>Though these drugs may have significant side effects, more research is necessary to determine their usefulness in endometriosis treatment. By studying various drug dosages and regimens, researchers can aim to achieve effective treatment with minimal side effects. Personalized treatment based on illness severity can be achieved by selecting the right medication and dosage.</p><p><strong>Conclusion: </strong>Future research can include optimizing dosages in preclinical studies, comparing repurposed drugs to conventional therapies in randomized trials, and conducting longer and larger clinical trials further to assess side effects and effectiveness in endometriosis patients.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144815957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crocus sativus and Neurological Health: A Review on Depression and Impaired Neurogenesis.","authors":"Ayesha Sultana, Abdul Rahman Shafeeh, Mohammed Gulzar Ahmed, Abdul Rahamanulla, Gyas Khan, Md Sadique Hussain","doi":"10.2174/0113816128380974250716232813","DOIUrl":"https://doi.org/10.2174/0113816128380974250716232813","url":null,"abstract":"<p><p>Crocus sativus (saffron) is a valuable medicinal plant with a rich phytochemical profile, including bioactive carotenoids, flavonoids, and terpenoids. The key constituents of saffron-crocin, crocetin, picrocrocin, and safranal-exhibit potent neuroprotective properties, with crocin, a water-soluble carotenoid, playing a crucial role in promoting neurogenesis and mitigating depressive symptoms. Depression, affecting approximately 280 million individuals globally (WHO, 2023), is closely associated with impaired neurogenesis, highlighting the need for novel treatment strategies. Crocus sativus, particularly in its nanotherapeutic form, offers promise in the treatment of depression by effectively crossing the blood-brain barrier and modulating neurotransmitter systems. In addition to its carotenoids, saffron contains flavonoids, such as kaempferol and quercetin derivatives, which contribute to its antioxidant and anti-inflammatory activities. This review explores the phytochemical composition of Crocus sativus, its role in neurogenesis, and its potential as a therapeutic agent for depression and neurodegenerative disorders.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antimicrobial Resistance: Enzymes, Proteins, and Computational Resources.","authors":"Saurav Kumar Mishra, Kanchan Sharma, John J Georrge","doi":"10.2174/0113816128415482250721112427","DOIUrl":"https://doi.org/10.2174/0113816128415482250721112427","url":null,"abstract":"<p><p>Antimicrobial resistance (AMR) is an important health concern rooted in antibiotic misuse and overuse, resulting in drug-resistant bacteria. However, resistance to these antimicrobials developed as soon as they were administered. Several variables lead to the progression of antimicrobial resistance (AMR), making it a multifaceted challenge for healthcare systems worldwide, such as erroneous diagnosis, inappropriate prescription, incomplete treatment, and many more. Getting an in-depth idea about the mechanism underlying AMR development is essential to overcome this. This review aims to provide information on how various enzymes or proteins aid in the antimicrobial resistance mechanisms and also highlight the clinical perspective of AMR, emphasizing its growing impact on patient outcomes, and incorporate the latest recent data from the World Health Organisation (WHO), underscoring the global urgency of the AMR crisis, with specific attention to trends observed in recent years. Additionally, it is intended to provide ideas about inhibitors that can inhibit the mechanism of antibiotic resistance and also to provide an idea about numerous computational resources available that can be employed to predict genes and/or proteins and enzymes involved in various antibiotic resistance mechanisms.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}